BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Issues Earnings Results

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) posted its earnings results on Tuesday. The company reported ($705.20) EPS for the quarter, FiscalAI reports.

BridgeBio Oncology Therapeutics Stock Up 2.4%

BridgeBio Oncology Therapeutics stock opened at $9.42 on Thursday. The stock has a 50-day moving average price of $8.25 and a 200 day moving average price of $9.10. The company has a market capitalization of $754.64 million, a price-to-earnings ratio of -4.60 and a beta of 0.36. BridgeBio Oncology Therapeutics has a 52 week low of $7.00 and a 52 week high of $14.87.

Wall Street Analyst Weigh In

BBOT has been the subject of a number of recent research reports. Canaccord Genuity Group started coverage on shares of BridgeBio Oncology Therapeutics in a research note on Monday, May 11th. They issued a “buy” rating and a $23.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on BridgeBio Oncology Therapeutics in a research report on Wednesday, July 8th. They set an “overweight” rating and a $27.00 target price on the stock. Oppenheimer started coverage on BridgeBio Oncology Therapeutics in a report on Monday, June 22nd. They issued an “outperform” rating and a $22.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a research note on Thursday, June 18th. Finally, UBS Group downgraded BridgeBio Oncology Therapeutics to an “overweight” rating in a research report on Wednesday, July 8th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $24.80.

Hedge Funds Weigh In On BridgeBio Oncology Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Armistice Capital LLC boosted its holdings in shares of BridgeBio Oncology Therapeutics by 142.7% in the 4th quarter. Armistice Capital LLC now owns 1,000,000 shares of the company’s stock valued at $12,520,000 after acquiring an additional 588,000 shares during the last quarter. Laurion Capital Management LP increased its stake in shares of BridgeBio Oncology Therapeutics by 40.1% in the fourth quarter. Laurion Capital Management LP now owns 1,464,938 shares of the company’s stock worth $18,341,000 after acquiring an additional 419,138 shares during the period. Catalio Capital Management LP purchased a new position in shares of BridgeBio Oncology Therapeutics during the fourth quarter worth $5,142,000. Paradigm Biocapital Advisors LP raised its holdings in shares of BridgeBio Oncology Therapeutics by 21.2% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 2,261,749 shares of the company’s stock worth $28,317,000 after purchasing an additional 395,608 shares during the last quarter. Finally, Granahan Investment Management LLC acquired a new position in BridgeBio Oncology Therapeutics during the first quarter valued at $2,068,000. 54.89% of the stock is owned by hedge funds and other institutional investors.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.